Claim Missing Document
Check
Articles

Found 26 Documents
Search

Suitability Of Real Cost To Tariff Of INA-Cbgs Of Hypertensive Patients At X General Hospital Restyana, Anggi; Admaja, Wika
Jurnal Mandala Pharmacon Indonesia Vol. 10 No. 1 (2024): Jurnal Mandala Pharmacon Indonesia
Publisher : Program Studi Farmasi Universitas Mandala Waluya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35311/jmpi.v10i1.450

Abstract

Hypertension referred to as the "silent killer". Hypertension is a non-communicable disease that one of the leading causes death in the world. Increasing prevalence of hypertension based on measurements Indonesia in the population aged (18 years by 34.11% with the highest hypertension sufferers in South Kalimantan at 44.13% and the lowest prevalence of hypertension in Papua at 22.22%. In Indonesia, health costs keep increasing due to degenerative diseases. This study aims to determine the Real Cost of hypertensive patients and to determine the difference in Real Cost to the INA CBGs tariff of hypertensive inpatients at General Hospital X Kediri regarding the class of treatment, severity and length of treatment. This study was a descriptive quantitative research using a cross sectional design with retrospective data. The results of the study of the real cost of hospital of hypertensive patients with or without comorbidities at Public Hospital X Kediri was Rp.408,473,500. Meanwhile, the INA CBGs tariff was Rp.211,709,100 so that the difference obtained was negative Rp.196,764,400. The cost consists of class 1 treatment (13 patients) was Rp. (-32,884,800), class 2 (16 patients) was Rp. (-25,262,600) and class 3 (79 patients) was Rp. (-138,617,000). The difference in severity was mild severity (81 patients) of Rp. (-144,856,800), moderate severity (20 patients) of Rp. (-39,647,000) and severe severity (7 patients) of Rp. (-12,260,600). The difference in length of hospital stay 0-5 days (66 patients) was Rp.(-85,504,600), length of hospital stay 6-10 days (41 patients) was Rp.(-107,463,600) and length of hospital stay (10 days (1 patient) was Rp.(-3,796,200). The real cost of hospital was greater than the INA CBGs tariff, thus causing a negative cost difference that can make financial loss to the hospitals.
Cost Effectiveness Analysis of Antibiotics in Appendicitis Surgery Patients at Kediri City Hospital Restyana, Anggi; Admaja, Wika; Wibisono, Adi
Jurnal Mandala Pharmacon Indonesia Vol. 10 No. 2 (2024): Jurnal Mandala Pharmacon Indonesia
Publisher : Program Studi Farmasi Universitas Mandala Waluya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35311/jmpi.v10i2.617

Abstract

Pre and post-appendicitis guideline therapy include broad-spectrum antibiotics before surgery, appendectomy (laparoscopic or open), and follow-up antibiotics post-surgery in complicated cases of appendicitis. The incidence of appendicitis is estimated to be around 100 cases per 100,000 people per year, with a consistent incidence rate in Western countries and an increasing trend in developing regions. In Indonesia, there are 24.9 cases of acute appendicitis per 10,000 people. The use of antibiotics in appendicitis surgery has been widely used. In most studies, it is known that the most widely used types of prophylactic antibiotics are second or third generation cephalosporins or a combination of metronidazole, either given as a single dose, two or three doses. However, there has been no research on direct comparisons between antibiotics. Most studies have not found significant differences in the incidence of SSI. In Indonesia, health financing uses the National Health Insurance system which requires cost-effective therapy. This study aims to determine the cost-effectiveness between the use of cefoperazone-metronidazole and ceftriaxone. The perspective in this study uses the perspective of health care facilities. Costs are observed in two classes of care and effectiveness is measured through the incidence of Surgical Wound Infection. The results of cefoperazone-metronidazole antibiotic therapy compared to ceftriaxone in insurance patients obtained an ICER value of Rp 94,380.68,-. So the use of cefoperazone-metronidazole antibiotics will incur additional costs of Rp 94,380.68,- per increase in therapy outcomes. While in the analysis of the cost-effectiveness of cefoperazone-metronidazole antibiotic therapy compared to ceftriaxone in non-insured patients, the average cost was lower with higher effectiveness with cefoperazone-metronidazole antibiotic therapy than using therapy with ceftriaxone antibiotics. Thus, cefoperazone-metronidazole antibiotics can be considered as the main choice in non-insured patient therapy. In this study, no relationship was found between demographic factors, type of appendicitis and class of care on the incidence of surgical wound infections.
Evaluasi Biaya Riil, Tarif Ina-Cbgs Dan Lama Rawat Pada Gastroenteritis Di Rs X Kediri 2024: Penelitian Anggi Restyana; Hanik Mariana Dewi; Wika Admaja
Jurnal Pengabdian Masyarakat dan Riset Pendidikan Vol. 3 No. 4 (2025): Jurnal Pengabdian Masyarakat dan Riset Pendidikan Volume 3 Nomor 4 (April 2025
Publisher : Lembaga Penelitian dan Pengabdian Masyarakat

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.31004/jerkin.v3i4.517

Abstract

Gastroenteritis merupakan masalah kesehatan utama di Indonesia, termasuk di Kota Kediri, dengan prevalensi tinggi yang membebani sistem kesehatan. Penelitian ini bertujuan menganalisis perbandingan biaya riil dan tarif INA-CBGs untuk pasien gastroenteritis peserta JKN di RS X Kediri. Metode penelitian menggunakan desain cross-sectional dengan data retrospektif. Pengambilan sampel menggunakan metode total sampling dari 259 pasien rawat inap periode Januari–Desember 2024. Data biaya riil diperoleh dari rekam medis dan instalasi farmasi, lalu dibandingkan dengan tarif INA-CBGs menggunakan uji statistik deskriptif dan uji beda (t-test). Hasil menunjukkan biaya riil per pasien di kelas 1, 2, dan 3 masing-masing sebesar Rp1.230.000, Rp1.450.000, dan Rp1.680.000, sedangkan tarif INA-CBGs untuk kelas yang sama adalah Rp2.150.000, Rp2.300.000, dan Rp2.500.000. Selisih rata-rata biaya riil dan tarif INA-CBGs signifikan (p<0,001) dengan variasi tinggi (standar deviasi >25%). Tidak adanya perbedaan signifikan (p-value 0,182) dalam LOS antar kelas perawatan mengindikasikan standarisasi protokol perawatan yang baik, di mana semua pasien menerima kualitas perawatan yang serupa terlepas dari kelas perawatan yang mereka pilih.
Antibacterial Test Of Telang Flower Extract (Clitorea Ternatea L.) Against Pseudomonas Aeruginosa Luluk Aniqoh Meliana Putri; Chinthia Devientasari; Devita Riafinola Andaririt; Ivan Junius Mesak; Anggi Restyana
Strada Journal of Pharmacy Vol. 5 No. 2 (2023): October
Publisher : Universitas STRADA Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30994/sjp.v5i2.96

Abstract

The butterfly pea flower is a shrub that can grow and live for years (perennial), can reach a height of 5 meters, has fine hair, and is woody at the base, the flower color is bright blue with a yellowish white color in the middle. Butterfly pea flower (Clitoria ternatea L.) is a plant that has long been used in medicine and has been proven to contain alkaloid and flavonoid secondary metabolite compounds which have antibacterial potential. Antibacterials are substances that can interfere with the growth or even kill bacteria by interfering with the metabolism of harmful microbes. The aim of this research was to determine the inhibitory power of telang flower simplicia extract (Clitoria ternatea L.) on the growth of Pseudomonas aeruginosa bacteria. This research aims to test the activity of butterfly pea flowers, namely by maceration using 70% ethanol solvent. For antibacterial testing using the disk diffusion method. Extracts are made in various concentrations of 10%, 20%, 30%. The positive control used was Chloramphenicol. The results of this research were that the average zone of inhibition of butterfly pea flower extract against Pseudomonas aeruginosa bacteria was 1.48 mm at 10% concentration, 2.41 mm at 20% concentration, and 5.70 mm at 30% concentration. These results show that butterfly pea flower extract has antibacterial activity against Pseudomonas aeruginosa bacteria, although the resulting inhibitory power is not strong. At a concentration of 30% butterfly pea flower extract, it has the greatest inhibitory effect on the growth of Pseudomonas aeruginosa bacteria than concentrations of 10% and 20%.
Analisis Efektifitas Biaya Terapi Antibiotik Profilaksis Cefazoline dan Ceftriaxone pada Pasien Badan Penyelenggara Jaminan Sosial Kesehatan Rawat Inap Bedah Fraktur di RSU Madiun Wika Admaja; Faldy Faldy; Anggi Restyana; Kumala Sari P.D.W
JUMANTIK (Jurnal Ilmiah Penelitian Kesehatan) Vol 10, No 2 (2025)
Publisher : Prodi Kesehatan Masyarakat Fakultas Kesehatan Masyarakat UIN Sumatera Utara

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30829/jumantik.v10i2.23667

Abstract

In general, the treatment of fractures carried out is a surgical procedure, so the use of prophylactic antibiotic therapy is needed, including cefazoline antibiotics and ceftriaxone antibiotics. To determine the effectiveness value of the therapy outcome and the direct medical costs in patients who received prophylactic antibiotics cefazoline and ceftriaxone in fracture surgery cases in 2023 at Madiun Hospital. This study was conducted with an observational analytical approach and used a cross-sectional design carried out retrospectively using the provider's perspective. The study analyzed the direct medical cost and clinical outcomes is no incidence of surgical wound infection while the patient was receiving inpatient care at the hospital. Sampling was carried out using a purposive sampling technique. The research indicate that the direct medical cost of prophylactic cefazolin is IDR 10,517,114, while for ceftriaxone, it's IDR 10,027,158. Statistically, this difference was found to be significant with a p-value of 0.096. Regarding clinical outcomes, no surgical site infections were found with either cefazolin or ceftriaxone administration. Based on the direct medical costs incurred by patients and the clinical outcomes achieved, the Average Cost-Effectiveness Ratio (ACER) for cefazolin was calculated at IDR 10,517,114, and for ceftriaxone at IDR 10,027,158. Subsequently, the Incremental Cost-Effectiveness Ratio (ICER) was calculated, yielding a value of IDR 489,956. This suggests that using cefazolin is not more cost-effective than ceftriaxone, as the use of cefazolin would incur an additional cost of IDR 489,956 each treatment outcome. Antibiotic prophylactic cefazolin was not more cost-effective than ceftriaxone, with an ICER of Rp. 489,956.
Analisa Biaya Penggunaan Seftriakson dan Siprofloksasin Pasien Infeksi Saluran Kemih di Rumah Sakit X Kabupaten Jombang Tahun 2017 Anggi Restyana; Wika Admaja
PHARMACY: Jurnal Farmasi Indonesia (Pharmaceutical Journal of Indonesia) PHARMACY: Jurnal Farmasi Indonesia (Pharmaceutical Journal of Indonesia), Vol. 16 No. 02 Desember 20
Publisher : Universitas Muhammadiyah Purwokerto

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30595/pharmacy.v16i2.5847

Abstract

Jumlah penderita Infeksi Saluran Kemih (ISK) mencapai 90-100 kasus per 100.000 penduduk per tahun. Dalam penanganannya berbagai macam antibiotik digunakan sebagai terapi pengobatan termasuk siprofloksasin. Saat ini siprofloksasin merupakan antibiotik pilihan pertama dalam terapi ISK di Rumah Sakit X Kabupaten Jombang. Penelitian ini bertujuan untuk membandingkan biaya terapi penggunaan antibiotik seftriakson dan siprofloksasin pada pasien infeksi saluran kemih. Telah dilakukan penelitian cost effectiveness analysis menggunakan metode observasi analitik dengan rancangan secara cross-sectional, pengambilan data secara retrospektif dengan menelusur dokumen rekam medis pasien. Metode analisis menggunakan statistic uji-t tidak berpasangan. Penelitian dilakukan pada perspektif rumah sakit. Populasi dalam penelitian ini sebanyak 164 pasien. Terdapat 64 pasien yang memenuhi kriteria inklusi. Sebanyak 32 pasien mendapatkan siprofloksasin dan 32 pasien mendapatkan seftriakson. Total biaya langsung rata-rata pasien ISK yang mendapatkan seftriakson adalah Rp902.908,3 sedangkan pasien yang mendapatkan siprofloksasin adalah Rp959.918,91. Efektivitas diukur berdasarkan probabilitas lama rawat yang ditentukan. Pasien dengan seftriakson memiliki lama rawat 4,468 hari dengan probabilitas 0,875 dan siprofloksasin memiliki lama rawat 4,688 hari dengan probabilitas 0,781.  Berdasarkan efektivitas, nilai ACER seftriakson sebesar Rp1.031.895,28 dan nilai ACER siprofloksasin sebesar Rp1.229.089,51. Namun secara uji statistik tidak ditemukan perbedaan yang bermakna pada efektivitas dan biaya antara seftriakson dan siprofloksasin. Pada perhitungan nilai ICER pada penelitian ini didapatkan nilai sebesar Rp259.138,82. Artinya ada biaya tambahan sebesar Rp259.138,82 per outcome terapi.